Translations on this website are prepared by a third-party provider. Some portions may be incorrect. Some items—including downloadable files or images—cannot be translated at all. No liability is assumed by Beth Israel Deaconess Medical Center for any errors or omissions. Any user who relies on translated content does so at his/her own risk.

Contact Information

Beth Israel Deaconess Medical Center

Dr. Arai had been working in academic hospitals in Japan as a urologist and has performed clinical and basic research on urological cancers, especially castration-resistant prostate cancer (CRPC). To further understand the molecular basis of CRPC and pursue his career as a surgeon-scientist, he joined the Balk Lab in 2014. Since then, he has dedicated himself to discovering novel therapies
for lethal prostate cancer (PCa), primarily targeting the apoptosis pathway. During his time in the Balk Lab, Dr. Arai has also successfully generated a series of patient-derived PCa xenografts (PD
Xs), including a BRCA2-deficient model. Using these valuable PDX models he is investigating novel personalized therapies for patients with lethal PCa.